On November 26, 2019 Bristol-Myers Squibb Company (NYSE: BMY) reported that it will hold an investor webcast on Sunday, December 8, 2019 at 8:00 p.m. ET to discuss data presented at the American Society of Hematology (ASH) (Free ASH Whitepaper) meeting, in Orlando (Press release, Bristol-Myers Squibb, NOV 26, 2019, View Source [SID1234551681]). Company executives will provide an overview of data presented and address questions from investors and analysts.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and the general public are invited to listen to a live webcast of the event at investor.bms.com. Materials related to the event will be available at the same website prior to the event. A replay of the event will be available and can be accessed at investor.bms.com.

On November 26, 2019 Pacira BioSciences, Inc. (NASDAQ: PCRX) reported that it will present at the 31st Annual Piper Jaffray Healthcare Conference at 9:30 AM on Tuesday, December 3, 2019 (Press release, Pacira Pharmaceuticals, NOV 26, 2019, View Source [SID1234551714]). Live audio of the event can be accessed by visiting the "Events" page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 26, 2019 Alkermes plc (Nasdaq: ALKS) reported that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Evercore ISI 2nd Annual HealthCONx Conference on Tuesday, Dec. 3, 2019 at 8:00 a.m. ET (1:00 p.m. GMT) from Boston (Press release, Alkermes, NOV 26, 2019, https://www.prnewswire.com/news-releases/alkermes-to-present-at-the-evercore-isi-2nd-annual-healthconx-conference-300965572.html [SID1234551731]). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 26, 2019 ExCellThera Inc., an advanced biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, reported that data from a Phase I/II clinical trial using its lead technology, ECT-001, will be presented at the 61st Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper) in Orlando, Florida (Press release, ExCellThera, NOV 26, 2019, View Source [SID1234551699]). Details of the presentation are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date & Time: Sunday, December 8, 2019; 6:00-8:00 p.m. ET
Title: UM171 Modified Cord Blood Achieves Excellent Survival and Disease Control after 2 Years of Follow-up in High and Very High Risk Malignancies
Abstract Number: 3245
Lead Author: Sandra Cohen, MD, FRCP(C), Division of Hematology and Medical Oncology, Stem Cell Transplant Program, Department of Medicine, University of Montreal and Maisonneuve-Rosemont Hospital, Montreal, QC, Canada
Location: Orange County Convention Center, Hall B

About ECT-001
The ECT-001 technology is a combination of a small molecule, UM171, and an optimized culture system. The technology, capable of expanding the number of stem and immune cells exponentially in as little as seven days, is used in novel curative cord blood transplant therapies for patients with blood cancers, allowing rapid engraftment, greatly reduced incidence of transplant-related mortality, low risk of chronic graft-versus-host disease and low risk of relapse, resulting in better outcomes for patients.

On November 26, 2019 Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, reported that Lorence Kim, M.D., Chief Financial Officer will participate in the 31st Annual Piper Jaffray Healthcare Conference in New York City on December 3rd at 9:00 a.m. ET (Press release, Moderna Therapeutics, NOV 26, 2019, View Source [SID1234551715]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Moderna website at View Source A replay of the webcast will be archived on Moderna’s website for 30 days following the presentation.